Hi all, just something to read and ponder about any potential impacts to DXB-200 revenues/ profits if the below can be an alternative drug in reducing protein urea although from a different indication. I am not smart enough to understand it so posting it here so someone may educate me.
I am a believer in DXB.. not down ramping.
https://www.biopharmadive.com/news/apellis-drug-pegcetacoplan-success-kidney-disease-trial/723699/
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
53.5¢ |
Change
-0.010(1.83%) |
Mkt cap ! $327.0M | |||
| Open | High | Low | Value | Volume |
| 54.5¢ | 54.5¢ | 53.0¢ | $133.1K | 248.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 49239 | 53.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 53.5¢ | 2650 | 1 |
View Market Depth
| Last trade - 10.04am 21/07/2025 (20 minute delay) ? |
| DXB (ASX) Chart |